Understanding the
interplay between

cancer, patient & therapy

Understanding the
interplay between

cancer, patient
and therapy

An integrated approach
to precision oncology

An integrated approach to
precision oncology

An integrated approach
to precision oncology

An integrated approach to
precision oncology

OncoHost is advancing a new paradigm in precision oncology.
The PROphet® platform combines AI and plasma proteomic profiling to assign a PROphet® Score, a
measure of the predicted clinical benefit from anti-PD-1/PD-L1 treatment correlated to the patient’s
overall survival, and list clinical evidence-based treatment considerations.

Plasma Proteomic Profiling

Analyzing the biological interplay of the patient, tumor, and therapy can:
Enable early prediction
of individual response to
anti-PD-1/PD-L1 immunotherapy
Provide actionable
clinical insights and
optimal therapy choices

A new approach to
managing therapeutic strategies

Blood-based test
Not exclusive to
mutation carriers
Personalized
PROphet® Report
Predictive
clinical insights
Clinical evidence-
based treatment
considerations

Contact us

US office

1110 SE Cary Parkway, Suite 205
Cary, North Carolina
27518
T. (855) 950-2112
E. [email protected]

Israel office

17 Hamelacha Street, Floor 1
Binyamina, Israel
3057324
T. +972 485 37558
E. [email protected]